BVXV, hits a 3-month low of $5.2, shedding -87.16%
In comparison, the broader Pharmaceuticals: Major Industry returned -23% over the same period. Tickeron A.I.dvisor analyzed 186 other stocks in the Pharmaceuticals: Major Industry over the last three months, and found that 30 of them (16.36%) exhibited an Uptrend while 156 of them (83.64%) exhibited a Downtrend. Current price $5.20 is below $5.76 the lowest support line found by Tickeron A.I. Throughout the month of 09/23/20 - 10/23/20, the price experienced a -87% Downtrend. During the week of 10/16/20 - 10/23/20, the stock fell -87%. Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for BVXV's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Indicator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BVXV advanced for three days, in 166 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
BVXV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The RSI Indicator entered the oversold zone -- be on the watch for BVXV's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Indicator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BVXV advanced for three days, in 166 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
BVXV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.